Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of
switching virologically suppressed adults living with HIV on bictegravir/tenofovir
alafenamide/emtricitabine to dolutegravir/lamivudine